
Advances in Dermatology Therapeutics: Key Insights from AAD 2025
Highlights include new data on roflumilast cream 0.15%, an investigational anti-OX40 ligand monoclonal antibody, and more.
At the
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

































































































































































































































































































